XML 57 R20.htm IDEA: XBRL DOCUMENT

Revenue (Tables)

6 Months Ended

Jun. 30, 2023

Revenue is presented by type, and net of deductions in the table below. The Group’s accounting policies for revenue and such deductions are disclosed in the consolidated financial statements of the Group for the year ended December 31, 2022.

	For the three months ended June 30,				For the six months ended June 30,
	2023 £’000		2022 £’000		2023 £’000		2022 £’000

Product revenue, net		45,514		23,992		87,566		31,674
Pre-product revenue, net		—		3,708		—		6,537
Total revenue from sale of therapies		45,514		27,700		87,566		38,211
Collaboration revenue
Eli Lilly		—		—		—		7,361
Genentech		2,250		4,302		4,739		8,904
Total collaboration revenue		2,250		4,302		4,739		16,265
Total revenue		47,764		32,002		92,305		54,476

Eli Lilly and Genentech are based in the United States. Net product revenue from the sale of KIMMTRAK, and net pre-product revenue from the sale of tebentafusp as part of a compassionate use and early access program are presented by region based on the location of the customer below.

	For the three months ended June 30,				For the six months ended June 30,
	2023 £’000		2022 £’000		2023 £’000		2022 £’000
United States		32,812		18,137		62,345		25,819
Europe		12,189		9,560		24,517		12,389
Rest of World		513		3		704		3
Total revenue from sale of therapies		45,514		27,700		87,566		38,211